Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SPOT +8.4%, DHR +6.7%, CR +6.3% (to also acquire CryoWorks), NVS +5.2%, GE +4.9%, GM +4.4%, PHM +4.4%, KMB +4.3%, SAP +3.9%, OPCH +3.6%, HSTM +3.4%, FBP +3%, ARE +2.8%, FI +2.7%, PNR +2.3%, MLI +2.3%, DGX +2.2%, GL +2.1%, RBB +2.1% (also appoints new CFO), CADE +1.8%, MEDP +1.6%, VLRS +1.6%, LMT +1.6%, CATY +1.4%, R +1.4%, UPS +1.3%, HAL +0.9%, HXL +0.8%, AGNC +0.7%, PNFP +0.7%, HRI +0.7%
Other news:
- IBRX +23.7% (receives FDA approval of ANKTIVA)
- HIBB +18.7% (to be acquired by JD Sports Fashion for $87.50 per share)
- CANG +8.2% (announces up to $50 mln new share repurchase program)
- ACET +7% (highlights preclinical data)
- LIND +6.5% (CFO to resign)
- NBIX +5.5% (reports positive phase 2 data for NBI-1065845 in adults with major depressive disorder)
- BGNE +3.1% (announces that the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across three indications, including first- and second-line use)
- AJG +2.2% (acquires Prasidium Credit Insurance)
- NGNE +2% (upcoming presentation of safety data)
- OSG +1.8% (awarded federal grant to design marine transport for liquified CO2 captured by Florida's largest emitters)
- HESM +1.1% (increases quarterly cash distribution)
Analyst comments:
- ATRC +4.8% (upgraded to Outperform from Perform at Oppenheimer)
- PENN +4.8% (upgraded to Buy from Hold at Truist)
- RBLX +4.7% (upgraded to Overweight from Neutral at JP Morgan)
- DDOG +2.9% (upgraded to Overweight from Equal Weight at Wells Fargo)
- FSLR +1.8% (upgraded to Outperform from In-line at Evercore ISI)
- MELI +1.2% (upgraded to Buy from Hold at DZ Bank)
- STM +0.7% (upgraded to Buy from Hold at Berenberg)